Home » FDA Steps Up Effort to Restrict Conflicts on Advisory Panels
FDA Steps Up Effort to Restrict Conflicts on Advisory Panels
The FDA is proposing to disclose a new detail in listing conflicts of interest for advisory committee members — the name of the company or institution
involved — as the agency’s head recommends that officials minimize conflicts of interest on panels. At present, the agency discloses only whether
a panel member’s financial interest is associated with the sponsor, a competitor or another affected company. The new recommendations are included
in a draft guidance. Comments are due June 21.
Devices & Diagnostics Letter
Devices & Diagnostics Letter
Upcoming Events
-
07May
-
14May
-
30May